We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+35.04%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$181M
Cap. Flow
-$1.32M
Cap. Flow %
-0.07%
Top 10 Hldgs %
41.59%
Holding
123
New
29
Increased
30
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$28.3M
2
ANAB icon
AnaptysBio
ANAB
+$26.6M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$20.4M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$19.6M
5
ERAS icon
Erasca
ERAS
+$17.1M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$58.6M
2
WVE icon
Wave Life Sciences
WVE
+$16.9M
3
CGEM icon
Cullinan Oncology
CGEM
+$14.8M
4
ACLX
Arcellx
ACLX
+$14.2M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.51%
2 Financials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$130M 6.72%
+200,000
New +$136M
APGE icon
2
Apogee Therapeutics
APGE
$10.1B
$108M 5.59%
1,284,926
+50,000
+4% +$3.63M
XENE icon
3
Xenon Pharmaceuticals
XENE
$6.47B
$97.4M 5.03%
1,675,000
+425,000
+34% +$19.6M
ERAS icon
4
Erasca
ERAS
$6.6B
$86.6M 4.47%
5,350,000
+1,450,000
+37% +$17.1M
INSM icon
5
Insmed
INSM
$23.3B
$78.5M 4.05%
480,000
+30,000
+7% +$4.61M
ROIV icon
6
Roivant Sciences
ROIV
$24.4B
$77.6M 4.01%
2,800,000
+1,100,000
+65% +$28.3M
SYRE icon
7
Spyre Therapeutics
SYRE
$8.17B
$64.5M 3.33%
1,279,134
-153,457
-11% -$5.79M
CNTA
8
DELISTED
Centessa Pharmaceuticals
CNTA
$55.6M 2.87%
1,400,000
+799,448
+133% +$20.4M
PRAX icon
9
Praxis Precision Medicines
PRAX
$8.59B
$54.8M 2.83%
170,000
-15,000
-8% -$4.64M
ANAB icon
10
AnaptysBio
ANAB
$1.6B
$52.1M 2.69%
940,000
+495,308
+111% +$26.6M
ALKS icon
11
Alkermes
ALKS
$8.66B
$47.7M 2.47%
1,350,000
+350,000
+35% +$10.9M
CYTK icon
12
Cytokinetics
CYTK
$10.9B
$46.2M 2.38%
700,483
-99,517
-12% -$6.32M
ABVX
13
Abivax
ABVX
$12B
$45.1M 2.33%
405,000
-100,000
-20% -$11.8M
TEVA icon
14
Teva Pharmaceuticals
TEVA
$37.5B
$42.2M 2.18%
1,400,000
– –
ACLX
15
DELISTED
Arcellx
ACLX
$41.7M 2.15%
362,764
-160,961
-31% -$14.2M
MRNA icon
16
CALL
Moderna
MRNA
$25.1B
$40.6M 2.1%
+800,000
New +$37.3M
NUVL
17
DELISTED
Nuvalent
NUVL
$30.7M 1.59%
300,000
-22,633
-7% -$2.31M
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
$29.7M 1.53%
562,631
+12,631
+2% +$519K
DNTH icon
19
Dianthus Therapeutics
DNTH
$5.21B
$29.4M 1.52%
350,000
+235,000
+204% +$13.6M
LXEO icon
20
Lexeo Therapeutics
LXEO
$358M
$29M 1.5%
5,050,211
+1,850,211
+58% +$13.1M
COGT icon
21
Cogent Biosciences
COGT
$6.48B
$28.9M 1.49%
750,000
+400,000
+114% +$14.8M
MDGL icon
22
Madrigal Pharmaceuticals
MDGL
$12.6B
$28.8M 1.49%
55,000
+23,869
+77% +$11.4M
STRO icon
23
Sutro Biopharma
STRO
$393M
$26.6M 1.38%
1,069,519
+321,137
+43% +$5.8M
FBRX icon
24
Forte Biosciences
FBRX
$921M
$26.2M 1.35%
1,011,890
+22,400
+2% +$645K
ORKA
25
Oruka Therapeutics
ORKA
$5.01B
$24.5M 1.27%
499,673
-302,669
-38% -$10.5M
1
2 3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Affinity Asset Advisors held 123 positions worth $1.94B, up 10% from $1.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors's Q1 2026 filing shows 29 new, 30 increased, 25 reduced and 18 closed positions. Its largest new stake was Enliven Therapeutics: 586,904 shares worth $23M. The largest sale was Ventyx Biosciences, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 77% a quarter earlier, followed by Financials.

  • Affinity Asset Advisors's largest Q1 2026 buy was Enliven Therapeutics: 586,904 shares worth $23M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q1 2026, an estimated $28.3M increase.
  • Affinity Asset Advisors's biggest Q1 2026 reduction was Wave Life Sciences, cutting an estimated $16.9M.
  • Affinity Asset Advisors fully exited Ventyx Biosciences in Q1 2026, selling an estimated $58.6M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.94B portfolio in Q1 2026.
  • Affinity Asset Advisors opened 29 new positions and closed 18 in Q1 2026.
  • Affinity Asset Advisors's portfolio value rose 10% quarter-over-quarter to $1.94B.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.